Hypertension in the ESRD patient: Pathophysiology, therapy, outcomes, and future directions

American Journal of Kidney Diseases

Volumn 32, Issue 5, 1998, Pages 705-719

  Mailloux, L U ^a   Haley, W E ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Chronic renal failure; End stage renal disease; Hypertension; Pathophysiology; Therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ERYTHROPOIETIN; LOSARTAN; METHYLDOPA; VALSARTAN; VERAPAMIL;

ANEMIA; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; NEPHROSCLEROSIS; OUTCOMES RESEARCH; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; XEROSTOMIA;

EID: 0031738832     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(98)70146-5     Document Type: Article

References (139)